Biopharmaceutical company specializing on developing safe and effective therapeutics for patients to address a number of mental health issues Cybin Inc. (NYSE: CYBN) (NEO: CYBN) announced publication of a peer reviewed article capturing 17 models of psychedelic-assisted psychotherapy.
The article was titled ‘Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model’ and it was published last week on the peer-reviewed journal Frontiers in Psychology.
The company also unveiled EMBARK, a leading edge model of psychedelic-assisted psychotherapy. According to Cybin, the desire to build upon the successes and avoid the shortcomings of previous approaches to psychedelic-assisted psychotherapy is what influenced the development of EMBARK.
“It’s a pleasure to see our work published in this respected journal. In developing EMBARK, we looked at 17 models of psychedelic-assisted psychotherapy, and we noticed that many are missing critical elements: a focus on ethics, on human relationships, on the body as a site of somatic healing, and on evidence-based practices. We designed EMBARK to overcome some of these limitations as an integrative model of psychedelic therapy. We’d like to honor the contributions of many teachers and leaders in the field who have helped chart this course,” said Cybin’s chief clinical officer and EMBARK’s co-creator, Alex Belser.
The article also captures an overview of the EMBARK’s six clinical domains namely E-Existential-Spiritual, M-Mindfulness, B-body Aware, A-Affective-Cognitive, R-Relational and K-Keeping Momentum. It further highlights the pros and cons of existing psychedelic-assisted psychotherapy approaches and evidence based therapies.
The article goes down as the first publication aimed at presenting EMBARK as an open-source model of practice and training for therapists and facilitators supporting psychedelic-based treatments.
